Biovica International AB (publ) (STO:BIOVIC.B)
Sweden · Delayed Price · Currency is SEK 0.5280
+0.0380 (7.76%)
Jul 24, 2026, 5:29 PM CET
Biovica International AB Company Description
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally.
It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation.
It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Biovica International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Theis Kipling |
Contact Details
Address: Dag Hammarskjölds väg 54B Uppsala, Uppsala County 752 37 Sweden | |
| Phone | 46 1 84 44 48 30 |
| Website | biovica.com |
Stock Details
| Ticker Symbol | BIOVIC.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | May - April |
| Reporting Currency | SEK |
| ISIN Number | SE0008613731 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Theis Kipling | Chief Executive Officer |
| Anders Moren | Chief Financial Officer and Secretary |
| Hanna Ritzén | Senior Vice President of Global Marketing and Business Development |
| Henrik Winther D.V.M., Ph.D. | Head and Senior Vice President of Pharma Services |
| Hector Tamburini | Head of US Laboratory Operations, Regulatory and Quality |